Who we are
Yatrex Pharmaceuticals is a next-generation biotech company pioneering breakthrough therapies for neurological and critical care disorders. Our core technology is built on a proprietary class of tricyclic polyarginine peptides that uniquely inhibit ASIC1a, a key ion channel involved in stroke, brain injury, and heart failure. With a pipeline that includes first-in-class peptide therapeutics and a repurposed small molecule platform, Yatrex is advancing innovative, brain-penetrant drugs with superior stability and efficacy. We are driven by scientific integrity, patient-centric innovation, and a vision to redefine the future of neuroprotection.
Contact us
Interested in working together? Fill out some info and we will be in touch shortly. We can’t wait to hear from you!